Kureha Of Japan Signs Development Agreement With LG Lifescience Indian Subsidiary
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Japanese chemical company Kureha Feb. 13 signed an agreement with Indian subsidiary of South Korean pharmaceutical company LG Lifescience. According to the agreement, LG Lifescience obtained exclusive rights to develop and market Kureha's proprietary oral absorbent chronic renal failure treatment Kremezin (AST-120) in India. The company plans a market launch in 2012. Currently available for therapeutic use in Japan, Taiwan and Korea, AST-120 is estimated to expand in other Asian countries as well as in the U.S. and Europe. (Click here for more - Japanese language
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.